The patent will expire in January 2025. Auxilium plans to list the patent promptly in approved drug products with therapeutic equivalence evaluations (commonly known as the Orange Book), published by the FDA. The companies have also announced that Bentley has filed a divisional application and continuations with the USPTO, which, if granted, may expand the scope of patent claims covering Testim.
Armando Anido, CEO and president of Auxilium, said: “We are very pleased that Testim now has patent protection through January 2025. Testim is a great product that continues to take market share and grow at a high rate, so extending our patent protection through January 2025 is an important accomplishment.”